Long-Term Safety and Effectiveness of Rituximab Biosimilar RTXM83: A Retrospective Extension Study in Brazilian Patients with Diffuse Large B-Cell Lymphoma-Reference-Cited by-同舟云学术

Long-Term Safety and Effectiveness of Rituximab Biosimilar RTXM83: A Retrospective Extension Study in Brazilian Patients with Diffuse Large B-Cell Lymphoma

Published:2024-06-03 Issue:3 Volume:12 Page:585-598
ISSN:2366-1070
Container-title:Oncology and Therapy
language:en
Short-container-title:Oncol Ther

Author:

Delamain Marcia Torresan^ORCID,Cardoso Ana Carolina Ferreira^ORCID,Pericole Fernando Vieira^ORCID,da Silva Araújo Sérgio Shusterschitz^ORCID,Fogliatto Laura^ORCID,Higashi Marcia^ORCID,Pereira Juliana^ORCID,da Silva Roberto Luiz^ORCID,Werutsky Gustavo^ORCID,de Paulo Giacon Radtke Patrícia^ORCID,Salvino Marco Aurélio^ORCID,Castilho Vivienne^ORCID

Funder

Libbs Farmaceutica

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40487-024-00282-7.pdf

Reference35 articles.

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. https://doi.org/10.3322/caac.20107.

2. Salvaro MM, Justo MD, Frassetto MD, et al. Análise epidemiológica das internações por linfoma não hodgkin no Brasil. Hematol Transfus Cell Ther. 2021;43:498. https://doi.org/10.1016/j.htct.2021.10.858.

3. Hallack Neto AE, Pereira J, Saboya R, et al. Estratificação de risco em linfoma difuso de grandes células B. Rev Bras Hematol Hemoter. 2006;28:296–300. https://doi.org/10.1590/S1516-84842006000400016.

4. Winter MC, Hancock BW. Ten years of rituximab in NHL. Expert Opin Drug Saf. 2009;8:223–35. https://doi.org/10.1517/14740330902750114.

5. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435–45. https://doi.org/10.1182/blood.V83.2.435.435.